Completed

Topical Dehydrex in Treating Recurrent Corneal Erosion

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Corneal Diseases+3

+ Eye Diseases

+ Pathologic Processes

Over 18 Years
+17 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: September 2001
See protocol details

Summary

Principal SponsorHolles Laboratories, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: September 1, 2001

Actual date on which the first participant was enrolled.

This study continues to provide Dehydrex to patients who have received it previously under other studies. Patients continue to be treated with their current dose of Dehydrex. Upward dose adjustments may be made as clinically indicated. Patients undergo eye exams every 3 to 4 months or more often. Downward dose titration will be attempted in patients who are stable, free of symptoms, and willing to attempt downward adjustments. In patients who are able to discontinue the medication, duration of healing will be determined. In those patients who experience a recurrence after discontinuing the medication, Dehydrex will be restarted at a dose higher than the minimum effective dose. After at least 8 weeks of treatment and resolution of symptoms, the dose may again be reduced. Further attempts to discontinue the medication will not be made. Completion date provided represents the completion date of the grant per OOPD records

Official TitleTopical Dehydrex in Treating Recurrent Corneal Erosion
NCT00029185
Principal SponsorHolles Laboratories, Inc.
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

300 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Corneal DiseasesEye DiseasesPathologic ProcessesRecurrencePathological Conditions, Signs and SymptomsDisease Attributes

Criteria

3 inclusion criteria required to participate
Clinical diagnosis of symptomatic recurrent corneal syndrome due to anterior membrane dystrophy or posttraumatic abrasion
Not responsive to standard medical therapy with artificial tears, hypertonic saline, or bandage soft contact lenses
At least 3 episodes of erosion within the past 4 months documented by slit lamp examination
14 exclusion criteria prevent from participating
Chronic atopic disease affecting the ocular surface or adnexa
Allergy to any component of the medications to be used
Active ocular surface infection due to bacteria, virus, or fungus
Dry eye, exposure, trichiasis, entropion, ectropion, or neurotrophic keratopathy
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Holles Laboratories, Inc.

Cohasset, United StatesOpen Holles Laboratories, Inc. in Google Maps
CompletedOne Study Center